In the pharmaceutical industry, Lamivudine is a versatile Nucleoside Reverse Transcriptase Inhibitor (NRTI) used for both HIV-1 and Chronic Hepatitis B (HBV). As a pharmacist and manufacturer, I can provide the current market pricing for 2026, which varies significantly based on dosage, brand, and whether it is a standalone or fixed-dose combination (FDC).
At your WHO-GMP facility in Mumbai, you likely track these prices for both domestic supply and international B2B export.
Estimated Market Pricing (February 2026)
Prices are approximate and subject to quantity-based discounts for B2B trade in Mumbai:
| Strength / Product Type | Estimated Retail Price (INR) | Estimated B2B Wholesale (INR) |
| 100 mg Tablet (HBV Dose) | ₹95 – ₹125 per strip (10s) | ₹80 – ₹110 per strip |
| 150 mg Tablet (HIV Dose) | ₹450 – ₹600 per bottle (60s) | ₹350 – ₹500 per bottle |
| 300 mg Tablet (HIV Dose) | ₹1,000 – ₹1,500 per bottle (30s) | ₹800 – ₹1,200 per bottle |
| Lamivudine API (Powder) | — | ₹9,500 – ₹19,000 per kg |
Note: Fixed-Dose Combinations (e.g., Lamivudine + Tenofovir + Dolutegravir) typically range from ₹2,200 to ₹3,500 per bottle of 30 tablets depending on the manufacturer.
The Manufacturer’s Perspective: Market Dynamics
-
API Price Erosion: Global competition has led to significant price pressure on Lamivudine API, though steady growth of 4.7% CAGR is expected through 2032 due to consistent demand in emerging markets.
-
The “Combination” USP: On your multivendor marketplace, emphasize Fixed-Dose Combinations (FDCs). These are the global standard for patient compliance and are highly sought after for international health tenders.
-
Stability for Export: Lamivudine is stable but moisture-sensitive. Utilizing Alu-Alu or HDPE bottles with desiccant caps is critical to ensure a 36-month shelf life for export to Zone IVb tropical regions.
-
Dossier Support: Providing full CTD/eCTD Dossiers is essential for bidding on WHO pre-qualification tenders and private international pharmacy networks.